GlobalData on MSN4d
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and ImfinziTagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
Zacks.com on MSN6d
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast CancerThe FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...
News Medical on MSN1d
AstraZeneca receives positive NICE recommendations for lung cancer treatmentAstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
The drug, Osimertinib—also known by its brand name Tagrisso and produced by AstraZeneca— which increases survival time ...
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback